Oct. 27, 2000 - HydroEye(TM), the first orally ingested formulation for the treatment of dry eye syndrome, received overwhelming response at the annual meeting of the American Academy of Ophthalmology (AAO) in Dallas, Texas, this week
Two double-blind cross-over clinical trials are currently underway to
document rapidly accumulating anecdotal evidence that this approach to dry eye syndrome could provide long-sought relief
One of those clinical trials is being conducted under the supervision of Dr. Richard L. Lindstrom, clinical professor of ophthalmology at the University of Minnesota
According to Dr. Spencer Thornton, MD, ScienceBased Health chief medical advisor, HydroEye(TM) is
blend of omega-6 fatty acids, mucin complex, and nutrient cofactors - a combination that helps prevent atrophy of the tear glands while supporting proper tear secretion by promoting the normal structure and function of the lacrimal glands, conjunctival goblet cells, and the mucin network. HydroEye(TM) also enhances the production of lactoferrin, a natural ocular antibiotic.
In response to consumer demand, the company began making its formulations available directly to consumers on its website, www.ScienceBasedHealth.com
ScienceBased Health is a physician-centric organization created to market research-based healthcare products via physician practices and the Internet. ScienceBased Health services a national network of over 1,000 prescribing physicians and more than 25,000 patients.